Cranbury, NJ, United States of America

Cornerstone Pharmaceuticals, Inc.

Calculating rank
USPTO Granted Patents = 10

% Expired Patents = 40.0



Trademarks = 2

Forward Citations = 82

Loading Chart...
Loading Chart...

8 inventors (with patents filed for the assignee):

goldMedal Robert J Rodriguez (7 out of 15 patents)

silverMedal Robert G L Shorr (5 out of 16 patents)

bronzeMedal Rajinder Bhasin (3 out of 8 patents)

4.  Robert G Shorr (3 out of 34 patents)

5.  Zuzana Zachar (2 out of 4 patents)

6.  Tom Kwok (2 out of 2 patents)

7.  Paul M Bingham (2 out of 7 patents)

8.  Sanjeev Luther (1 out of 1 patent)

9.  Robert A Rodriguez (24 patents)

10.  Robert GL Shorr (0 patent)


10 patents:

Company Overview
Cornerstone Pharmaceuticals, Inc. is a biopharmaceutical company based in Cranbury, New Jersey, focused on developing innovative therapies for cancer treatment. The company specializes in the research and development of novel small molecules that target metabolic pathways in cancer cells, aiming to improve patient outcomes. With a commitment to advancing cancer care, Cornerstone leverages its expertise in drug discovery and development to address unmet medical needs in oncology, contributing to the evolving landscape of cancer therapeutics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 17 2026

10 Patents

#17 in Cranbury, NJ

#1,106 in New Jersey

#29,966 in US

#56,291 in the World

Cranbury, NJ (US)
Cranbury, NJ, United States of America
Forward Citations = 82

8 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cornerstone Pharmaceuticals, Inc.. Retrieved from https://idiyas.com/company/cornerstone-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…